PNS-12 Antigens (Anti-Neuronal Antibody Profile)

What is Paraneoplastic Syndrome (PNS) 12 antigen panel test?

Paraneoplastic Neurological Syndromes (PNS) are rare disorders triggered by an immune response to a cancer elsewhere in the body, where antibodies mistakenly attack the nervous system. Paraneoplastic Syndrome (PNS) 12 antigen panel test detects autoantibodies against 12 specific neuronal antigens commonly associated with Paraneoplastic Neurological Syndromes (PNS).

Parameters: AMPHIPHYSIN, PNMA2, RI, YO, HU, RECOVERIN, SOX-1, TITIN, GAD-65, ZIC4, TR, CV2

Why consider Paraneoplastic Syndrome (PNS) 12 antigen panel test?

Paraneoplastic Syndrome (PNS) 12 antigen panel test can be considered

• To help diagnose paraneoplastic neurological syndromes
• To identify if neurological symptoms are related to an underlying cancer.
• To guide further cancer screening and management.
• To differentiate paraneoplastic syndromes from other neurological or autoimmune diseases.
• To aid in guiding treatment (immunotherapy and cancer treatment).
• Who should get tested for Paraneoplastic Syndrome (PNS) 12 antigen panel test?

Who should get tested for Paraneoplastic Syndrome (PNS) 12 antigen panel test?

Paraneoplastic Syndrome (PNS) 12 antigen panel test can be recommended for

• Patients presenting with neurological symptoms such as neuropathy, cerebellar degeneration, encephalitis, or myelopathy with suspected paraneoplastic cause.
• Patients with known cancer who develop unexplained neurological problems.
• Patients with neurological symptoms that are unexplained by other common causes and suspicion of a hidden malignancy.
• Individuals with symptoms suggesting autoimmune attack on the nervous system.

More Information about Paraneoplastic Syndrome (PNS) 12 antigen panel test

Other names: Paraneoplastic Antibody Panel, Anti-Neuronal Antibody Panel, Paraneoplastic Neurological Syndrome Panel

Paraneoplastic Neurological Syndromes (PNS) are a group of rare disorders that occur when cancer-fighting agents of the immune system (like antibodies or T-cells) mistakenly attack parts of the brain, spinal cord, peripheral nerves, or muscles. These syndromes are not caused directly by the tumor itself or its metastasis, but rather by an autoimmune response triggered by the cancer.

Prognosis depends on Type of PNS, Timeliness of cancer and PNS diagnosis, Type and stage of cancer and Response to immunotherapy. Some PNS improve with cancer treatment; others may lead to irreversible neurological damage despite therapy.